Study of Rifaximin Antibiotic Effects on Gut Microbiota and Metabolic Profiles in Adults With Small Intestinal Bacterial Overgrowth Using CapScan Capsule

What this Trial Is About

This research aims to evaluate the effect of the antibiotic rifaximin on the gut microbiota and metabolic profiles in patients diagnosed with Small Intestinal Bacterial Overgrowth SIBO. The study uses the CapScan collection capsule, a device designed to sample intestinal fluids for detailed analysis. The trial is a prospective, open-label, single-arm, non-randomized, multi-center study focusing on understanding how rifaximin treatment may alter gut bacterial composition and metabolism in people with SIBO. Participants will use the CapScan collection capsule to collect samples from their gastrointestinal tract. They will receive a prescribed two-week course of rifaximin for SIBO, which they must not have started before enrollment. The study includes a 56-day period during which the gut microbiota and metabolome are sampled and analyzed to assess changes associated with rifaximin treatment. Throughout the study, participants will undergo assessments including microbiome sampling and metabolic profiling using the CapScan capsule. Researchers will monitor changes in gut bacteria and metabolites over 56 days to measure the effects of rifaximin. Participants must comply with study requirements, including contraception for women of childbearing potential and completing study visits within the designated timeframe. The study aims to gather detailed information on how rifaximin influences gut microbial communities and their metabolic products in SIBO patients.

Evaluating the Effect Of Rifaximin on the Gut Microbiota and Metabolome in SIBO Using CapScan®